Business Context and Reporting Period
This Form 10-Q covers Schering-Plough Corporation for the quarterly and nine-month periods ended September 30, 1998. The company is a global pharmaceutical and animal health enterprise. The financial statements are unaudited and presented on a pre-split basis; a 2-for-1 stock split was approved on September 22, 1998, with distribution scheduled for December 2, 1998.
Key Financial Metrics
| Metric | Q3 1998 | Q3 1997 | 9M 1998 | 9M 1997 |
|---|---|---|---|---|
| Sales (Revenue) | $1,986 million | $1,709 million | $6,018 million | $4,997 million |
| Net Income | $432 million | $353 million | $1,337 million | $1,101 million |
| Diluted EPS | $0.58 | $0.48 | $1.80 | $1.49 |
| Operating Cash Flow (9M) | $1,528 million (vs. $1,362 million in 1997) | |||
| Cash and Equivalents | $937 million (as of Sept 30, 1998) | |||
| Debt (Short-term + Long-term) | $184 million (as of Sept 30, 1998) | |||
| Effective Tax Rate | 24.5% |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 16% in Q3 and 20% for the nine-month period compared to 1997. Organic growth (excluding currency) was 18% for the quarter and 23% for the nine months.
- Profitability: Net income rose 22% in Q3 and 21% for the nine months. Income before taxes represented 28.8% of sales in Q3 (up from 27.3%) and 29.4% for the nine months (up from 29.2%).
- Product Drivers:
- CLARITIN: Generated $635 million in Q3 and $1,758 million for the nine months, driving allergy/respiratory sales.
- Animal Health: Sales surged 105% for the nine months, largely due to the inclusion of the Mallinckrodt business acquired in 1997.
- Anti-infectives: Growth driven by Intron A and Rebetron Combination Therapy for hepatitis C.
- Expense Trends: Cost of sales as a percentage of sales increased slightly (to 19.9%) due to lower-margin Mallinckrodt products and higher royalties. SG&A as a percentage of sales decreased to 38.4% in Q3 (from 39.8%) as sales growth outpaced expense growth.
- Capital Allocation: The company repurchased $109 million of common shares and paid $465 million in dividends during the nine-month period. Short-term borrowings were reduced by $433 million.
Outlook, Risks, and Contingencies
- Legal Proceedings: The company is a defendant in over 160 antitrust actions regarding alleged price-fixing and refusal to sell at discounted prices. A federal class action was settled for approximately $22 million over three years. Several state cases remain pending, though management believes liabilities are not material and the actions are without merit.
- Year 2000 (Y2K) Compliance: The company estimates total project costs at $50 million, with $30 million incurred by September 30, 1998. Completion is expected by December 1999. The primary risk is potential disruption from third-party vendors (wholesalers, distributors) rather than internal systems.
- Regulatory and Competitive Risks: Operations face pressure from government-mandated cost containment, generic competition, and patent uncertainties. The company notes that the impact of future healthcare initiatives cannot be reasonably estimated.
- Stock Split: A 2-for-1 stock split is effective December 2, 1998. Pro-forma diluted EPS for the nine months ended Sept 30, 1998, would be $0.90.
Investor Verification Checklist
- Verify the impact of the Mallinckrodt acquisition on future margin trends, as it currently lowers the overall cost of sales ratio.
- Monitor the status of pending state antitrust class actions (specifically in California, Alabama, and Tennessee) for potential liability updates.
- Assess the progress of Y2K remediation with key third-party suppliers and distributors to evaluate supply chain risk.
- Confirm the execution of the 2-for-1 stock split and its effect on liquidity and share price in Q4 1998.
- Review the sustainability of CLARITIN sales growth given the competitive landscape for nonsedating antihistamines.